{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:45:50Z","timestamp":1766159150831,"version":"3.41.2"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults and affects mainly the skeletal muscle, heart, and brain. DM1 is caused by a CTG repeat expansion in the 3\u2032UTR region of the <jats:italic>DMPK<\/jats:italic> gene that sequesters muscleblind-like proteins, blocking their splicing activity and forming nuclear RNA <jats:italic>foci<\/jats:italic>. Consequently, many genes have their splicing reversed to a fetal pattern. There is no treatment for DM1, but several approaches have been explored, including antisense oligonucleotides (ASOs) aiming to knock down <jats:italic>DMPK<\/jats:italic> expression or bind to the CTGs expansion. ASOs were shown to reduce RNA <jats:italic>foci<\/jats:italic> and restore the splicing pattern. However, ASOs have several limitations and although being safe treated DM1 patients did not demonstrate improvement in a human clinical trial. AAV-based gene therapies have the potential to overcome such limitations, providing longer and more stable expression of antisense sequences. In the present study, we designed different antisense sequences targeting exons 5 or 8 of <jats:italic>DMPK<\/jats:italic> and the CTG repeat tract aiming to knock down DMPK expression or promote steric hindrance, respectively. The antisense sequences were inserted in U7snRNAs, which were then vectorized in AAV8 particles. Patient-derived myoblasts treated with AAV8. U7snRNAs showed a significant reduction in the number of RNA <jats:italic>foci<\/jats:italic> and re-localization of muscle-blind protein. RNA-seq analysis revealed a global splicing correction in different patient-cell lines, without alteration in <jats:italic>DMPK<\/jats:italic> expression.<\/jats:p>","DOI":"10.3389\/fcell.2023.1181040","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:32:38Z","timestamp":1686807158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Promising AAV.U7snRNAs vectors targeting DMPK improve DM1 hallmarks in patient-derived cell lines"],"prefix":"10.3389","volume":"11","author":[{"given":"Camila F.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Robriquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reid","family":"Neinast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lumariz","family":"Hernandez-Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanarajan","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. David","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim L.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Wein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/S41434-022-00316-7","article-title":"Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1","volume":"29","author":"Ait Benichou","year":"2022","journal-title":"Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/genes4020275","article-title":"Altered Ca2+ homeostasis and endoplasmic reticulum stress in Myotonic Dystrophy type 1 muscle cells","volume":"4","author":"Botta","year":"2013","journal-title":"Genes (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","article-title":"Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice","volume":"25","author":"Carrell","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1074\/jbc.M410781200","article-title":"MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1","volume":"280","author":"Dansithong","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","article-title":"Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts","volume":"94","author":"Davis","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0092-8674(87)90585-X","article-title":"Expression of a single transfected cDNA converts fibroblasts to myoblasts","volume":"51","author":"Davis","year":"1987","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"Star: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"666666","DOI":"10.3389\/FIMMU.2021.666666","article-title":"T cell-mediated immune responses to AAV and AAV vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nsmb.1958","article-title":"Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs","volume":"18","author":"Fran\u00e7ois","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An unstable triplet repeat in a gene related to myotonic muscular dystrophy","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nm.2374","article-title":"Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy","volume":"17","author":"Fugier","year":"2011","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/hmg\/10.19.2079","article-title":"Defective satellite cells in congenital myotonic dystrophy","volume":"10","author":"Furling","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0002-9440(10)63894-1","article-title":"Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy","volume":"162","author":"Furling","year":"2003","journal-title":"Am. J. Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/mt.2016.97","article-title":"Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy","volume":"24","author":"Gao","year":"2016","journal-title":"Mol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1038\/mtna.2013.9","article-title":"Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy","volume":"2","author":"Gonz\u00e1lez-Barriga","year":"2013","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B16","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1089\/HUM.2020.286","article-title":"Lack of toxicity in nonhuman primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1365-2443.2007.01112.x","article-title":"Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles","volume":"12","author":"Holt","year":"2007","journal-title":"Genes Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/ACS.BIOCHEM.7B01239","article-title":"Design of a \u201cmini\u201d nucleic acid probe for cooperative binding of an RNA-repeated transcript associated with myotonic dystrophy type 1","volume":"57","author":"Hsieh","year":"2018","journal-title":"Biochemistry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.omtn.2020.11.014","article-title":"Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.3390\/IJMS23094622","article-title":"Molecular therapies for myotonic dystrophy type 1: From small drugs to gene editing","volume":"23","author":"Izzo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/NG0796-316","article-title":"Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice","volume":"13","author":"Jansen","year":"1996","journal-title":"Nat. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/acschembio.8b00646","article-title":"Furamidine rescues myotonic dystrophy type i associated mis-splicing through multiple mechanisms","volume":"13","author":"Jenquin","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population based prevalence of myotonic dystrophy type 1 using genetic analysis of state-wide blood screening program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol. Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/1756-0500-4-490","article-title":"Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules","volume":"4","author":"Larsen","year":"2011","journal-title":"BMC Res. Notes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2012.0404","article-title":"Systemic delivery of a peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy","volume":"23","author":"Leger","year":"2013","journal-title":"Nucleic Acid. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1089\/HUM.2021.047","article-title":"U7 snRNA, a small RNA with a big impact in gene therapy","volume":"32","author":"Lesman","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/BIOINFORMATICS\/BTT656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/NAR\/GKZ401","article-title":"WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs","volume":"47","author":"Liao","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/cdd.2010.33","article-title":"Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells","volume":"17","author":"Loro","year":"2010","journal-title":"Cell Death Differ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1242\/dmm.027367","article-title":"Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds","volume":"10","author":"Ludovic","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","article-title":"Flash: Fast length adjustment of short reads to improve genome assemblies","volume":"27","author":"Mago\u010d","year":"2011","journal-title":"Bioinformatics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","article-title":"Myotonic dystrophy mutation: An unstable CTG repeat in the 3\u2032 untranslated region of the gene","volume":"255","author":"Mahadevan","year":"1992","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","article-title":"Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat","volume":"289","author":"Mankodi","year":"2000","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Mol. Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/J.OMTM.2019.12.008","article-title":"Immune response mechanisms against AAV vectors in animal models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/JAMANEUROL.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","article-title":"Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy","volume":"106","author":"Mulders","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/mt.2011.191","article-title":"Stabilization of expanded (CTG) (CAG) repeats by antisense oligonucleotides","volume":"19","author":"Nakamori","year":"2011","journal-title":"Mol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ana.23992","article-title":"Splicing biomarkers of disease severity in myotonic dystrophy","volume":"74","author":"Nakamori","year":"2013","journal-title":"Ann. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/1875397301004010009","article-title":"Hts-compatible patient-derived cell-based assay to identify small molecule modulators of aberrant splicing in myotonic dystrophy type 1","volume":"4","author":"O\u2019Leary","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/JPET.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1","volume":"355","author":"Pandey","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.yexcr.2016.02.013","article-title":"Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts","volume":"342","author":"Pantic","year":"2016","journal-title":"Exp. Cell Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","article-title":"CRISPR\/Cas9-Mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients","volume":"9","author":"Provenzano","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1038\/ncomms8205","article-title":"Abnormal splicing switch of DMD\u2019s penultimate exon compromises muscle fibre maintenance in myotonic dystrophy","volume":"6","author":"Rau","year":"2015","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"20991","DOI":"10.1073\/pnas.1901893116","article-title":"A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels","volume":"116","author":"Reddy","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/NG0796-325","article-title":"Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy","volume":"13","author":"Reddy","year":"1996","journal-title":"Nat. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/FIMMU.2020.00670\/BIBTEX","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"R116","DOI":"10.1093\/hmg\/ddr343","article-title":"Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: New findings and future challenges","volume":"20","author":"Sicot","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"ISCB Comm J-1408","DOI":"10.12688\/f1000research.9005.3","article-title":"RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR","volume":"5","author":"Smyth","year":"2018","journal-title":"F1000Research"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","article-title":"AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1","volume":"48","author":"Stepniak-Konieczna","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1083\/jcb.128.6.995","article-title":"Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues","volume":"128","author":"Taneja","year":"1995","journal-title":"J. Cell Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol. Clin."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.3390\/ijms22168607","article-title":"Transcriptome analysis in a primary human muscle cell differentiation model for myotonic dystrophy type 1","volume":"22","author":"Todorow","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e11752","DOI":"10.7554\/eLife.11752","article-title":"A new view of transcriptome complexity and regulation through the lens of local splicing variations","volume":"5","author":"Vaquero-Garcia","year":"2016","journal-title":"Elife"},{"key":"B58","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/S41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"","journal-title":"Nat. Rev. Drug Discov."},{"key":"B59","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cell.2012.06.041","article-title":"Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins","volume":"150","author":"Wang","year":"2012","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/HMG\/DDY432","article-title":"Transcriptome alterations in myotonic dystrophy skeletal muscle and heart","volume":"28","author":"Wang","year":"","journal-title":"Hum. Mol. Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omtm.2022.07.005","article-title":"Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse","volume":"26","author":"Wein","year":"2022","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","article-title":"Targeting nuclear RNA for in vivo correction of myotonic dystrophy","volume":"488","author":"Wheeler","year":"2012","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","article-title":"Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA","volume":"325","author":"Wheeler","year":"2009","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/nar\/gkv163","article-title":"Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy","volume":"43","author":"Wojtkowiak-Szlachcic","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00418-015-1315-5","article-title":"Dynamic changes of nuclear RNA foci in proliferating DM1 cells","volume":"143","author":"Xia","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/hmg\/ddaa060","article-title":"Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3 UTR RNA","volume":"29","author":"Yadava","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"B67","doi-asserted-by":"publisher","first-page":"109906","DOI":"10.1016\/j.forsciint.2019.109906","article-title":"RNA sequencing reveals abnormal LDB3 splicing in sudden cardiac death","volume":"302","author":"Yamamoto","year":"2019","journal-title":"Forensic Sci. Int."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1181040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:32:44Z","timestamp":1686807164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1181040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":67,"alternative-id":["10.3389\/fcell.2023.1181040"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1181040","relation":{},"ISSN":["2296-634X"],"issn-type":[{"type":"electronic","value":"2296-634X"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"1181040"}}